DIRECT BIOLOGICS
Live / Applied — Response to non-final action entered (as of 23 Mar 2026)
What this means for you
Not registered yet, but its 27 Aug 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99361536
- Mark type
- Stylized text
- Filed
- 27 Aug 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 001 — Chemicals: Exosomes for use in the manufacture of cosmetics and pharmaceuticals
- Class 005 — Pharmaceuticals: Pharmaceutical and therapeutic preparations for the treatment of inflammation, inflammation-derived diseases, acute respiratory disease syndrome (ARDS), Crohn’s disease, perianal fistulizing disease, colitis, pulmonary fibrosis, hair loss, alopecia, psoriasis, ulcers, joint pain, discogenic pain, lumbar and cervical radiculopathy, osteoarthritis, COVID-19, hip labral tears, traumatic brain injury, amyotrophic lateral sclerosis (ALS), chronic regional pain syndrome (CRPS), facial nerve damage, Bell’s Palsey, Ehler’s Danlos Disease, wound care, and skin damage; pharmaceutical and therapeutic preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders; regenerative medicine, namely, pharmaceuticals and therapeutics for the treatment of inflammation, inflammation-derived diseases, acute respiratory disease syndrome (ARDS), Crohn’s disease, perianal fistulizing disease, colitis, pulmonary fibrosis, hair loss, alopecia, psoriasis, ulcers, joint pain, discogenic pain, lumbar and cervical radiculopathy, osteoarthritis, COVID-19, hip labral tears, traumatic brain injury, amyotrophic lateral sclerosis (ALS), chronic regional pain syndrome (CRPS), facial nerve damage, Bell’s Palsey, Ehler’s Danlos Disease, wound care, and skin damage; regenerative medicine, namely, pharmaceuticals and therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders
- Class 044 — Medical, beauty and agricultural services: Gene therapy; cell therapy; services in the field of regenerative medicine; diagnosing the need for, and administering, regenerative medicine; regenerative medicine services
Owner
- Direct Biologics, LLC, Austin, TX, US
Prosecution history
- 23 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 23 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 23 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 21 Jan 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 21 Jan 2026 — NON-FINAL ACTION E-MAILED
- 21 Jan 2026 — NON-FINAL ACTION WRITTEN
- 19 Jan 2026 — ASSIGNED TO EXAMINER
- 16 Jan 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 Aug 2025 — APPLICATION FILING RECEIPT MAILED
- 27 Aug 2025 — NEW APPLICATION ENTERED